Glucagon‑like peptide 1 receptor agonists (GLP‑1 RA) are approved for weight reduction and have recognized cardiometabolic benefits. Despite growing clinical interest, real‑world evidence is limited on how GLP‑1 RA use affects healthcare resource utilization (HCRU) and costs among older adults with heart failure (HF) and obesity, particularly within Medicare Advantage (MA) populations.
The investigators used a prevalent new‑user observational design and analyzed the Humana Healthcare Research database to identify MA beneficiaries with HF and obesity. Individuals were categorized as receiving standard HF therapy alone or HF therapy plus newly initiated GLP‑1 RA between January 1, 2022, and December 31, 2023. The primary comparisons focused on adjusted, one‑year mean differences in all‑cause and HF‑related HCRU and costs.
The study matched beneficiaries into pairs for comparison; the abstract reports results for 4,677 matched pairs. Specific covariates used for matching and adjustment were not detailed in the abstract. Outcomes reported include risk ratios for utilization measures (inpatient admissions, avoidable hospitalizations, emergency department visits) and percent differences in cost components (total, pharmacy, medical).
The matched cohort included 4,677 pairs of Medicare Advantage beneficiaries. The mean age in the study population was 72 years, and 41% of participants were male. Additional demographic or clinical characteristics beyond age and sex were not reported in the abstracted material.
When comparing beneficiaries who received HF therapy plus GLP‑1 RA with those who received HF therapy alone, the one‑year, adjusted risk estimates reported in the source were:
The authors also report that HF‑related HCRU measures were lower among beneficiaries who augmented HF therapy with GLP‑1 RA compared with those on HF therapy alone. The abstract does not provide the exact HF‑specific numeric estimates in the summary text available here.
These utilization findings indicate a reduced likelihood of inpatient admissions and avoidable hospitalizations in the year following initiation of GLP‑1 RA in this matched MA cohort, while ED visit rates were essentially unchanged.
The study reported one‑year mean differences in cost components between the two groups. Key reported findings were:
Together, these results indicate that while medical expenditures (non‑pharmacy) showed a small decrease, the overall total cost increase was driven by substantially higher pharmacy costs in the GLP‑1 RA group.
In this cohort of Medicare Advantage beneficiaries with HF and obesity, adding GLP‑1 RA to standard HF therapy was associated with lower rates of inpatient admissions and avoidable hospitalizations over one year compared with HF therapy alone. Emergency department utilization did not differ meaningfully. Although medical costs were slightly lower, total costs increased due to much higher pharmacy spending associated with GLP‑1 RA use.
The authors frame these findings as real‑world evidence that GLP‑1 RA augmentation of HF therapy may reduce certain types of acute care utilization in older adults with HF and obesity. As presented in the source, specific causal inferences, subgroup analyses, or sensitivity checks are not detailed in the abstracted content.
The report is a preprint and has not undergone peer review. The authors declared no competing interests. The Humana Human Subject Protection Office determined that the study did not constitute human subjects research and did not require institutional review board oversight under HHS regulations and relevant guidance.
De‑identified data supporting the results may be made available by the research team under conditions that include collaboration with study investigators, external funding for administrative and investigator time, demonstration of appropriate qualifications and human subjects protections training, and adherence to data use agreements. Requests for proprietary data such as pricing information would be considered case‑by‑case and may not be approved.
Limitations and additional methodological details (for example, the list of covariates used for matching/adjustment, duration of prior HF therapy, HF severity, or comorbidity burden) were not fully reported in the abstract and summary available from the source. The study’s preprint status should be noted when interpreting results.